Ryan Carbaugh, DO
Gastroenterology · Danville, KYNPI 1437541570
Payments from drug & device makers
Across 488 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Boston Scientific$979
- Takeda Pharmaceuticals U.S.A., Inc.$802
- Johnson & Johnson$430
- Ironwood Pharmaceuticals, Inc$261
- plus $3K from 32 others
What the payments were for
- Travel & lodging$5436%
- Food & beverage$9,12294%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 197 | $3,517 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 52 | $1,029 |
| Boston Scientific | 9 | $979 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $802 |
| Johnson & Johnson | 25 | $430 |
| Ironwood Pharmaceuticals, Inc | 17 | $261 |
| Pfizer | 10 | $240 |
| Sanofi | 11 | $216 |
| Daiichi Sankyo Inc. | 18 | $214 |
| Novo Nordisk | 8 | $196 |
| Intercept Pharmaceuticals, Inc. | 11 | $152 |
| Regeneron Healthcare Solutions, Inc. | 6 | $150 |
| Madrigal Pharmaceuticals | 4 | $144 |
| Amgen | 7 | $124 |
| Lilly USA, LLC | 6 | $99 |
| Gilead | 4 | $89 |
| Ferring Pharmaceuticals Inc. | 5 | $87 |
| Jazz Pharmaceuticals Inc. | 3 | $78 |
| Eisai Inc. | 4 | $72 |
| Boehringer Ingelheim | 3 | $70 |
| Janssen Scientific Affairs, LLC | 1 | $69 |
| Phathom Pharmaceuticals, Inc. | 3 | $63 |
| Nestle Healthcare Nutrition Inc. | 4 | $61 |
| Redhill Biopharma Inc. | 4 | $58 |
| QOL Medical, LLC | 3 | $58 |
| Merck | 2 | $52 |
| Braintree Laboratories, Inc. | 3 | $45 |
| Shire North American Group Inc | 2 | $45 |
| UCB, Inc. | 3 | $43 |
| Bristol Myers Squibb | 3 | $40 |
| Ardelyx, Inc. | 2 | $34 |
| GSK | 2 | $33 |
| Grifols USA, LLC | 2 | $28 |
| Concordia Pharmaceuticals Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Vivus LLC | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Shionogi Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$315
- Skyrizi$125
- TRULANCE$124
- Saxenda$104
How this compares
$9,665 in reported general payments places this provider in the 75th percentile of 207 gastroenterology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $334,144 |
| Humira(Cf) PenAdalimumab | 17 | $216,746 |
| LinzessLinaclotide | 81 | $61,227 |
| XifaxanRifaximin | 17 | $56,851 |
| IbsrelaTenapanor Hcl | 18 | $34,323 |
| MovantikNaloxegol Oxalate | 36 | $16,058 |
| TrulancePlecanatide | 14 | $9,872 |
| Esomeprazole Magnesium | 107 | $4,750 |
| Dexlansoprazole DrDexlansoprazole | 24 | $4,167 |
| Mesalamine | 15 | $4,138 |
| Omeprazole | 261 | $2,802 |
| Azathioprine | 14 | $2,781 |
| Lubiprostone | 26 | $2,470 |
| Ursodiol | 12 | $1,733 |
| Colestipol Hcl | 16 | $1,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $430 | $334,14413 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,029 | $66,72331 claims |
| AbbVieLinzess | $3,517 | $61,22781 claims |
| Ardelyx, Inc.Ibsrela | $34 | $34,32318 claims |
| Redhill Biopharma Inc.Movantik | $58 | $16,05836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 207 gastroenterology providers in Kentucky.
Other gastroenterology in Danville
- Gerald DrydenLouisville$3.5M
- Michael JonesCrestview Hills$1.9M
- Jens RosenauLexington$1.6M
- Matthew CaveLouisville$916K
- Deborah FlomenhoftLexington$905K
- Michael KreaseLouisville$694K
- Zahid SaeedCrestview Hills$442K
- Thomas AbellLouisville$375K
- Sunana SohiLouisville$220K
- Jeffrey TuvlinLouisville$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.